{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:08:27Z","timestamp":1768165707886,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04568-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:55:09Z","timestamp":1767880509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Latanoprost\/timolol fixed-dose combination: two decades of efficacy and safety in glaucoma management"],"prefix":"10.1186","volume":"26","author":[{"given":"Jose","family":"Martinez-de-la-Casa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Corsino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Tatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani Ohri","family":"Vignesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"4568_CR1","unstructured":"WHO. Eyelid inflammation Conjunctivitis Dry eye [Internet]. 2019. Available from: http:\/\/www.who.int\/publications-detail\/world-report-on-vision"},{"key":"4568_CR2","doi-asserted-by":"crossref","unstructured":"EGS. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. British Journal of Ophthalmology. 2021;105(Suppl 1):1\u2013169.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"4568_CR3","doi-asserted-by":"crossref","unstructured":"Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the Past, Present, and predictions for the future. Cureus. 2020.","DOI":"10.7759\/cureus.11686"},{"issue":"8","key":"4568_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.18240\/ijo.2023.08.09","volume":"16","author":"AB Azal","year":"2023","unstructured":"Azal AB, Tang SF, Othman O, Din NM. Efficacy and safety of latanoprost\/timolol fixed combination dosed twice daily compared to once daily in patients with primary open angle glaucoma. Int J Ophthalmol. 2023;16(8):1243\u20139.","journal-title":"Int J Ophthalmol"},{"key":"4568_CR5","doi-asserted-by":"crossref","unstructured":"Cordeiro MF, Gandolfi S, Gugleta K, Normando EM, Oddone F. How Latanoprost changed glaucoma management. Acta Ophthalmol. 2024;102(2).","DOI":"10.1111\/aos.15725"},{"issue":"4","key":"4568_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/IJG.0b013e3181e08121","volume":"20","author":"A Alm","year":"2011","unstructured":"Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost\/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215\u201322.","journal-title":"J Glaucoma"},{"key":"4568_CR7","doi-asserted-by":"crossref","unstructured":"Micheletti JM, Shultz M, Singh IP, Samuelson TW. An emerging multi-mechanism and multi-modal approach in interventional glaucoma therapy. Ophthalmol Ther. 2024.","DOI":"10.1007\/s40123-024-01073-z"},{"key":"4568_CR8","unstructured":"Aptel F, Chiquet C, Romanet JP. Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues."},{"issue":"7","key":"4568_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence. Ophthalmology. 2015;122(7):1308\u201316.","journal-title":"Ophthalmology"},{"issue":"6","key":"4568_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ogla.2019.07.005","volume":"2","author":"JT Le","year":"2019","unstructured":"Le JT, Mohanty K, Bicket AK, Tarver ME, Eydelman MB, Li T. Identifying outcomes that are important to patients with ocular hypertension or primary Open-Angle glaucoma. Ophthalmol Glaucoma. 2019;2(6):374\u201382.","journal-title":"Ophthalmol Glaucoma"},{"issue":"4\u20135","key":"4568_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","volume":"14","author":"AL Robin","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019;14(4\u20135):199\u2013210.","journal-title":"Expert Rev Ophthalmol"},{"key":"4568_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2025.03.025","volume":"275","author":"C Baudouin","year":"2025","unstructured":"Baudouin C, Myers JS, Van Tassel SH, Goyal NA, Martinez-de-la-Casa J, Ng A, et al. Adherence and persistence on prostaglandin analogues for glaucoma: A systematic review and Meta-Analysis. Am J Ophthalmol. 2025;275:99\u2013113.","journal-title":"Am J Ophthalmol"},{"key":"4568_CR13","doi-asserted-by":"crossref","unstructured":"Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence. 2021;15:1477\u201389.","DOI":"10.2147\/PPA.S264926"},{"issue":"5","key":"4568_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/eye.2011.45","volume":"25","author":"S Vandenbroeck","year":"2011","unstructured":"Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (PRO\u2019s) in glaucoma: a systematic review. Eye. 2011;25(5):555\u201377.","journal-title":"Eye"},{"issue":"13","key":"4568_CR15","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1517\/14656566.2013.813482","volume":"14","author":"AG Konstas","year":"2013","unstructured":"Konstas AG, Mocan MC, Katsanos A, Voudouragkaki IC, Irkec M. Latanoprost\/timolol fixed combination for the treatment of glaucoma. Expert Opin Pharmacother. 2013;14(13):1815\u201327.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"4568_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/BF02849907","volume":"24","author":"S Dunker","year":"2007","unstructured":"Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of Latanoprost and timolol. Adv Ther. 2007;24(2):376\u201386.","journal-title":"Adv Ther"},{"issue":"10","key":"4568_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00417-008-0875-7","volume":"246","author":"HJM Beckers","year":"2008","unstructured":"Beckers HJM, Schouten JSAG, Webers CAB, van der Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2008;246(10):1485\u201390.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"key":"4568_CR18","unstructured":"5.Urcelay_2004_PROM_compliance abstract."},{"issue":"4","key":"4568_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/jop.2012.0186","volume":"29","author":"L Quaranta","year":"2013","unstructured":"Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, et al. Prostaglandin analogs and Timolol-Fixed versus unfixed combinations or monotherapy for Open-Angle glaucoma: A systematic review and Meta-Analysis. J Ocul Pharmacol Ther. 2013;29(4):382\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"4568_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/108076803322472971","volume":"19","author":"TJ Zimmerman","year":"2003","unstructured":"Zimmerman TJ, Stewart WC. Intraocular Pressure, Safety, and quality of life in glaucoma patients switching to Latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405\u201315.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"4568_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/112067210401400508","volume":"14","author":"F Haverkamp","year":"2004","unstructured":"Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular Pressure, safety and quality of life in glaucoma patients switching to Latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol. 2004;14(5):407\u201315.","journal-title":"Eur J Ophthalmol"},{"key":"4568_CR22","unstructured":"Gautam N, Satyapal RK. Comparative efficacy and tolerability of latanoprost versus timolol in treating patients with chronic angle closure glaucoma. International Journal of Pharmaceutical and Clinical Research Original Research Article [Internet]. 2024;16(6):1774\u20137. Available from: https:\/\/www.ijpcr.com. https:\/\/impactfactor.org\/PDF\/IJPCR\/16\/IJPCR,Vol16,Issue6,Article331.pdf"},{"issue":"14","key":"4568_CR23","first-page":"5097","volume":"53","author":"G Kostas","year":"2012","unstructured":"Kostas G, Boboridis AG, Konstas, Victoria Toumanidou AT, Dimopoulos, Dimitrios G, Mikropoulos G, Moumtzis, et al. A 6-Month, observational trial investigating with electronic monitoring the level of adherence and ocular surface health with Latanoprost\/Timolol fixed versus Latanoprost and timolol unfixed therapy in glaucoma. Invest Ophthalmol Vis Sci. 2012;53(14):5097\u20135097.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"4568_CR24","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.3390\/jcm12093137","volume":"12","author":"V Toumanidou","year":"2023","unstructured":"Toumanidou V, Diafas A, Georgiadis N, Tsinopoulos I. Fixed versus unfixed combination of topical Latanoprost\/Timolol for glaucoma: an observational study investigating the level of adherence and ocular surface health. J Clin Med. 2023;12(9):3137.","journal-title":"J Clin Med"},{"issue":"1","key":"4568_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2415-10-21","volume":"10","author":"O Schwenn","year":"2010","unstructured":"Schwenn O, Heckmann B, Guzy C, Miller PJ. Long-term effect of latanoprost\/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study. BMC Ophthalmol. 2010;10(1):21.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"4568_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12886-021-01813-w","volume":"21","author":"C Shirai","year":"2021","unstructured":"Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare\/pharmacy claims database: a retrospective non-interventional cohort study. BMC Ophthalmol. 2021;21(1):52.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"4568_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.amjopharm.2007.05.004","volume":"5","author":"MJ Bhosle","year":"2007","unstructured":"Bhosle MJ, Reardon G, Camacho FT, Anderson RT, Balkrishnan R. Medication adherence and health care costs with the introduction of Latanoprost therapy for glaucoma in a medicare managed care population. Am J Geriatr Pharmacother. 2007;5(2):100\u201311.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"4","key":"4568_CR28","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0149-2918(03)80074-7","volume":"25","author":"G Reardon","year":"2003","unstructured":"Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clin Ther. 2003;25(4):1172\u201385.","journal-title":"Clin Ther"},{"issue":"10","key":"4568_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/bjo.2004.043232","volume":"88","author":"T Hamacher","year":"2004","unstructured":"Hamacher T. Short term efficacy and safety in glaucoma patients changed to the Latanoprost 0.005%\/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004;88(10):1295\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"4568_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","volume":"240","author":"N Pfeiffer","year":"2002","unstructured":"Pfeiffer N. A comparison of the fixed combination of Latanoprost and timolol with its individual components. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2002;240(11):893\u20139.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"7","key":"4568_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/archopht.120.7.915","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ. Latanoprost and timolol combination therapy vs monotherapy. Arch Ophthalmol. 2002;120(7):915.","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"4568_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/112067211002000411","volume":"20","author":"P Palmberg","year":"2010","unstructured":"Palmberg P, Kim EE, Kwok KK, Tressler CS. A 12-Week, Randomized, Double-Masked study of fixed combination Latanoprost\/Timolol versus Latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010;20(4):708\u201318.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"4568_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","volume":"128","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ. Fixed combination of Latanoprost and timolol vs individual components for primary Open-Angle glaucoma or ocular hypertension. Arch Ophthalmol. 2010;128(2):165.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"4568_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/02713680902850075","volume":"34","author":"AGP Konstas","year":"2009","unstructured":"Konstas AGP, Pikilidou MI, Tsironi S, Mikropoulos D, Kozobolis VP, Sarafidis PA, et al. 24-Hour intraocular pressure and blood pressure levels with Latanoprost\/Timolol fixed combination versus timolol. Curr Eye Res. 2009;34(5):369\u201377.","journal-title":"Curr Eye Res"},{"issue":"1","key":"4568_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/bjo.2009.162107","volume":"94","author":"R Varma","year":"2010","unstructured":"Varma R, Hwang LJ, Grunden JW, Bean GW. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination Latanoprost\/timolol versus Latanoprost or timolol monotherapy. Br J Ophthalmol. 2010;94(1):80\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"4568_CR36","first-page":"879","volume":"7","author":"Y Xing","year":"2014","unstructured":"Xing Y, Jiang FG, Li T. Fixed combination of Latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014;7(5):879\u201390.","journal-title":"Int J Ophthalmol"},{"issue":"2","key":"4568_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","volume":"111","author":"DH Shin","year":"2004","unstructured":"Shin DH, Feldman RM, Sheu WP. Efficacy and safety of the fixed combinations latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111(2):276\u201382.","journal-title":"Ophthalmology"},{"issue":"12","key":"4568_CR38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/sj.eye.6701446","volume":"18","author":"AGP Konstas","year":"2004","unstructured":"Konstas AGP, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of Latanoprost 0.005%\/timolol maleate 0.5% and dorzolamide 2%\/timolol maleate 0.5%. Eye. 2004;18(12):1264\u20139.","journal-title":"Eye"},{"issue":"5","key":"4568_CR39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/112067210901900517","volume":"19","author":"I Januleviciene","year":"2009","unstructured":"Januleviciene I, Ehrlich R, Siesky B, Nedzelskien\u00e9 I, Harris A, Visual Function. Optic nerve Structure, and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combinations. Eur J Ophthalmol. 2009;19(5):790\u20137.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"4568_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5005\/jp-journals-10028-1039","volume":"46","author":"S Ratol","year":"2012","unstructured":"Ratol S, Walia R, Chaudhry M. A comparative analysis of the efficacy and safety of fixed combinations of Latanoprost\/Timolol vs Dorzolamide\/Timolol in primary open angle glaucoma or ocular hypertension. J Postgrad Med Educ Res. 2012;46(4):172\u20136.","journal-title":"J Postgrad Med Educ Res"},{"issue":"4","key":"4568_CR41","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s10792-017-0601-8","volume":"38","author":"S Guven Yilmaz","year":"2018","unstructured":"Guven Yilmaz S, Degirmenci C, Karakoyun YE, Yusifov E, Ates H. The efficacy and safety of bimatoprost\/timolol maleate, latanoprost\/timolol maleate, and travoprost\/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018;38(4):1425\u201331.","journal-title":"Int Ophthalmol"},{"key":"4568_CR42","doi-asserted-by":"crossref","unstructured":"Kelly J, Ondategui. Pasto, Lop, Kelly. Randomized trial comparing three fixed combinations of prostaglandins\/prostamide with timolol maleate. Clin Ophthalmol. 2011;187.","DOI":"10.2147\/OPTH.S16666"},{"issue":"4","key":"4568_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/eye.2008.148","volume":"23","author":"A Martinez","year":"2009","unstructured":"Martinez A, Sanchez M. Bimatoprost\/timolol fixed combination vs latanoprost\/timolol fixed combination in open-angle glaucoma patients. Eye. 2009;23(4):810\u20138.","journal-title":"Eye"},{"issue":"5","key":"4568_CR44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1185\/030079907X182149","volume":"23","author":"A Martinez","year":"2007","unstructured":"Martinez A, Sanchez M. A comparison of the safety and intraocular pressure Lowering of bimatoprost\/timolol fixed combination versus latanoprost\/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007;23(5):1025\u201332.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"4568_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ajo.2010.05.003","volume":"150","author":"M Centofanti","year":"2010","unstructured":"Centofanti M, Oddone F, Gandolfi S, Hommer A, Boehm A, Tanga L, et al. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in Open-Angle glaucoma patients previously treated with Latanoprost plus timolol fixed combination. Am J Ophthalmol. 2010;150(4):575\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4568_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/112067210701700206","volume":"17","author":"F Topouzis","year":"2007","unstructured":"Topouzis F, Melamed S, Danesh-meyer H, Wells AP, Kozobolis V, Wieland H, et al. A 1-Year study to compare the efficacy and safety of Once-Daily Travoprost 0.004%\/Timolol 0.5% to Once-Daily Latanoprost 0.005%\/Timolol 0.5% in patients with Open-Angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(2):183\u201390.","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"4568_CR47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s12325-018-0718-9","volume":"35","author":"K Suzuki","year":"2018","unstructured":"Suzuki K, Otsuka N, Hizaki H, Hashimoto M, Kuwayama Y, Multicenter. Randomized, controlled study comparing Tafluprost\/Timolol fixed combination with Latanoprost\/Timolol fixed combination in primary Open-Angle glaucoma and ocular hypertension. Adv Ther. 2018;35(6):796\u2013808.","journal-title":"Adv Ther"},{"issue":"9","key":"4568_CR48","doi-asserted-by":"publisher","first-page":"e45079","DOI":"10.1371\/journal.pone.0045079","volume":"7","author":"JW Cheng","year":"2012","unstructured":"Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular Pressure-Lowering effects of commonly used Fixed-Combination drugs with timolol: A systematic review and Meta-Analysis. PLoS ONE. 2012;7(9):e45079.","journal-title":"PLoS ONE"},{"issue":"1","key":"4568_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.13.1.21","volume":"13","author":"H Feng","year":"2024","unstructured":"Feng H, Han D, Lu W, Tang G, Zhang H, Fan S, et al. Efficacy of morning versus evening Latanoprost\/Timolol fixed combination for Open-Angle glaucoma and ocular hypertension: A randomized clinical trial. Transl Vis Sci Technol. 2024;13(1):21.","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"4568_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.17116\/oftalma202213803182","volume":"138","author":"EV Karlova","year":"2022","unstructured":"Karlova EV, Zolotarev AV. Fixed combination of Latanoprost and timolol in the long-term treatment of patients with normal-tension glaucoma. Vestn Oftalmol. 2022;138(3):82.","journal-title":"Vestn Oftalmol"},{"issue":"2","key":"4568_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1248\/bpb.b15-00584","volume":"39","author":"S Fuma","year":"2016","unstructured":"Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, et al. Neuroprotective effect of ocular hypotensive drugs: Latanoprost\/Timolol in combination are more effective than each as monotherapy in RGC-5. Biol Pharm Bull. 2016;39(2):192\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"12","key":"4568_CR52","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","volume":"102","author":"A Alm","year":"1995","unstructured":"Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once Daily, evening or morning. Ophthalmology. 1995;102(12):1743\u201352.","journal-title":"Ophthalmology"},{"issue":"4","key":"4568_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12325-016-0302-0","volume":"33","author":"AGP Konstas","year":"2016","unstructured":"Konstas AGP, Quaranta L, Bozkurt B, Katsanos A, Garcia-Feijoo J, Rossetti L, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33(4):481\u2013517.","journal-title":"Adv Ther"},{"issue":"3","key":"4568_CR54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ajo.2004.04.022","volume":"138","author":"JHK Liu","year":"2004","unstructured":"Liu JHK, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and Latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389\u201395.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4568_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bjo.2003.018234","volume":"88","author":"M Diestelhorst","year":"2004","unstructured":"Diestelhorst M. A 12 week study comparing the fixed combination of Latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88(2):199\u2013203.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4568_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2415-11-23","volume":"11","author":"JL Zhao","year":"2011","unstructured":"Zhao JL, Ge J, Li XX, Li YM, Sheng YH, Sun NX, et al. Comparative efficacy and safety of the fixed versus unfixed combination of Latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011;11(1):23.","journal-title":"BMC Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04568-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T18:03:10Z","timestamp":1768154590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-025-04568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4568"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04568-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"JMMDLC has received financial grants from Santen, Ivantis, AbbVie, Viatris, Glaukos, and Thea. Additionally, JMMDLC has served as a consultant for AbbVie, Santen, Alcon, Viatris, Novartis, Thea, Bausch & Lomb, Glaukos, AJL, Visufarma, and Angellini. JMMDLC has been a speaker for AbbVie, Santen, Alcon, Viatris, Novartis, Thea, Bausch & Lomb, Glaukos, iCare, and Angellini. PCFV has received financial grants from Pharmacia, Pfizer, Bausch-Lomb, Alcon, Santen, Novartis, and Thea. Additionally, PCFV has served as a consultant for Pharmacia, Pfizer, Bausch-Lomb, Alcon, Allergan, Santen, Novartis, and Thea. PCFV has been a speaker for Pharmacia, Pfizer, Bausch-Lomb, Alcon, Allergan, Santen, Novartis, and Thea. AG has received financial grants from Alcon, Bausch & Lomb, Zeiss, Teleon, CooperVision, Hoya, Essilor, Santen, Viatris, Polpharma, Thea, and Johnson & Johnson. Additionally, AG has served as a consultant for Thea, Santen, Polpharma, Viatris, Eyerising, Essilor, and Alcon. AG has been a speaker for Thea, Santen, Polpharma, Viatris, Eyerising, Essilor, and Alcon. AT has served as a consultant for AbbVie, Viatris, Alcon, Sight Sciences, and Thea. Additionally, AT has received financial grants from AbbVie, Nova Eye Medical, and iStar Medical. AT has been a speaker for Alcon, Viatris, Sight Sciences, Thea, and Nova Eye Medical. SOV is an employee at Viatris and has no other conflicts of interest. TH is an employee and holds shares of Viatris.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}